Niagen Bioscience, Inc. (NAGE)

NCM – Real Time Price. Currency in USD

3.09

+0.01 (0.16%)

Market open: Aug 12, 2026, 3:35 PM EDT

3.03

-0.05 (-1.62%)

Previous after-hours: Aug 11, 2026, 7:55 PM EDT

Stock details

Previous close: 3.0764$
Day's range: 3.04 - 3.11$
52-week range: 2.87 - 10.52$
Volume: 93 549
Average volume: 833 999
Beta: 0.81
EPS (TTM): 0.2
PE ratio (TTM): 16.35
Forward P/E: 21.33
Market cap: 243 423 218
Shares outstanding: 79 125 997
Dividend yield: N/A
Next earnings date: 2026-11-04
Sector: Healthcare
Industry: Biotechnology

About the company

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and de... read more

CEO: Robert Fried
Country: United States
IPO Date
Employees: 117
Fiscal Year End: January - December
Website: https://www.niagenbioscienc...

Revenue Breakdown

Consumer Products / 75.47%

Ingredients / 22.16%

Analytical Reference Standards and Services / 2.38%

News

No Data

There are no news for this stock.

Chart: NAGE

Loading Chart...

Overall Score

5 / 1050%

Octagon View

Strength & Weakness

Company's cash reserves $66.7M significantly exceed its total debt $2.3M, ensuring strong financial flexibility

Total current assets $97.8M exceed Total current liabilities $15.1M, highlighting excellent liquidity

Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management

The company has no interest-bearing debt, showcasing excellent financial strength

The company generates positive free cash flow $2.7M, supporting its financial health

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	6.50	6.05	10
Quick ratio	5.13	5.63	10
Debt to Equity	0.03	0.30	9.0
Debt to Assets	0.02	1.04	9.0
Interest coverage	N/A	-16.91	10
Weighted average score			9.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	72M	84M	100M	129M	129M
Gross Profit	43M	51M	62M	83M	83M
Operating Income	-9M	-2M	8M	14M	9M
Net Income	-17M	-5M	9M	17M	16M
EBITDA	-7M	-194K	9M	16M	11M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	64.84	-11.73	10
Operating margin %	2.35	-24.60	2.0
Net margin %	3.23	-172.20	3.0
EBITDA margin %	3.93	-201.27	2.0
Cash flow margin %	9.31	-156.39	5.0
Weighted average score			4.4

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	20.38	-57.97	10
ROE	29.03	-63.56	10
ROIC	28.15	-42.57	10
ROCE	2.63	-71.10	5.0
Weighted average score			8.8

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	1.34	-56.67	2.0
Next quarter	13.9	3.33	6.0
Current year	3.65	-27.5	2.5
Next year	15.77	6.21	7.0
Weighted average score			4.4

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-5.36	-84.75	-85.7	313.78	3.3
Y/Y	-4.27	-73.31	-74.99	141.93	3.3
3y average	21.71	148.87	136.6	75.83	10
5y average	17.15	89.9	85.72	27.11	9.8
Weighted average score					6.6

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	16.05	-5.25	6.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	2.00	64.66	6.4
P/B	2.92	2.96	5.0
Weighted average score			4.6

DCF Model

DCF Model Period5 years

Discount rate12%

Perpetual growth rate3%

Revenue 5 year CAGR14.88%

FCF 5 year CAGR4

Fair value2.64$

Stock price3.07$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$2.64

UndervaluedStock priceOvervalued

$3.07

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Robert Fried

Country

United States

IPO Date

Employees

117

Fiscal Year End

January - December

Website

https://www.niagenbioscienc...

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

6.50

6.05

Quick ratio

5.13

5.63

Debt to Equity

0.03

0.30

9.0

Debt to Assets

0.02

1.04

9.0

Interest coverage

N/A

-16.91

Weighted average score

9.6

METRIC

2022

2023

2024

2025

TTM

Total Revenue

72M

84M

100M

129M

Gross Profit

43M

51M

62M

83M

Operating Income

-9M

-2M

14M

Net Income

-17M

-5M

17M

16M

EBITDA

-7M

-194K

16M

11M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

64.84

-11.73

Operating margin %

2.35

-24.60

2.0

Net margin %

3.23

-172.20

3.0

EBITDA margin %

3.93

-201.27

2.0

Cash flow margin %

9.31

-156.39

5.0

Weighted average score

4.4

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

20.38

-57.97

ROE

29.03

-63.56

ROIC

28.15

-42.57

ROCE

2.63

-71.10

5.0

Weighted average score

8.8

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

1.34

-56.67

2.0

Next quarter

13.9

3.33

6.0

Current year

3.65

-27.5

2.5

Next year

15.77

6.21

7.0

Weighted average score

4.4

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-5.36

-84.75

-85.7

313.78

3.3

Y/Y

-4.27

-73.31

-74.99

141.93

3.3

3y average

21.71

148.87

136.6

75.83

5y average

17.15

89.9

85.72

27.11

9.8

Weighted average score

6.6

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

16.05

-5.25

6.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

2.00

64.66

6.4

P/B

2.92

2.96

5.0

Weighted average score

4.6

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Niagen Bioscience, Inc. (NAGE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Niagen Bioscience, Inc. (NAGE)

Stock details

About the company

Revenue Breakdown

News

Chart: NAGE

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$2.64

$3.07

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: NAGE

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$2.64

$3.07

Economic Moat